{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Squamous+Cell+Non-small+Cell+Lung+Cancer&page=2", "query": { "condition": "Squamous Cell Non-small Cell Lung Cancer", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Squamous+Cell+Non-small+Cell+Lung+Cancer&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-07-24T16:54:10.981Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03729596", "title": "MGC018 With or Without MGA012 in Advanced Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Squamous Cell Carcinoma of Head and Neck", "Triple Negative Breast Cancer", "Melanoma", "Advanced Solid Tumor, Adult", "Metastatic Castrate Resistant Prostate Cancer", "Non Small Cell Lung Cancer" ], "interventions": [ { "name": "vobramitamab duocarmazine", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "MacroGenics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 143, "start_date": "2018-11-21", "completion_date": "2023-03-18", "has_results": true, "last_update_posted_date": "2025-07-31", "last_synced_at": "2026-07-24T16:54:10.981Z", "location_count": 9, "location_summary": "Santa Monica, California • Washington D.C., District of Columbia • Baltimore, Maryland + 5 more", "locations": [ { "city": "Santa Monica", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Grand Rapids", "state": "Michigan" }, { "city": "Omaha", "state": "Nebraska" } ], "official_url": "https://clinicaltrials.gov/study/NCT03729596" }, { "nct_id": "NCT01995188", "title": "A Study to Evaluate the Safety and Pharmacology of DNIB0600A in Participants With Platinum-Sensitive Ovarian Cancer or Non-Squamous Non-small Cell Lung Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Non-Squamous Non-Small Cell Lung Cancer" ], "interventions": [ { "name": "Bevacizumab", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "DNIB0600A", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Genentech, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 41, "start_date": "2013-12-16", "completion_date": "2016-11-09", "has_results": false, "last_update_posted_date": "2017-10-04", "last_synced_at": "2026-07-24T16:54:10.981Z", "location_count": 4, "location_summary": "Boston, Massachusetts • Oklahoma City, Oklahoma • Nashville, Tennessee", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Oklahoma City", "state": "Oklahoma" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT01995188" }, { "nct_id": "NCT03474497", "title": "UCDCC#272: IL-2, Radiotherapy, and Pembrolizumab in Patients Refractory to Checkpoint Blockade", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Non Small Cell Lung Cancer", "Metastatic Melanoma", "Metastatic Renal Cell Carcinoma", "Head and Neck Squamous Cell Carcinoma" ], "interventions": [ { "name": "IL-2", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Radiotherapy", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "Megan Daly, MD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 18, "start_date": "2019-05-20", "completion_date": "2026-02", "has_results": true, "last_update_posted_date": "2026-01-29", "last_synced_at": "2026-07-24T16:54:10.981Z", "location_count": 2, "location_summary": "Sacramento, California", "locations": [ { "city": "Sacramento", "state": "California" }, { "city": "Sacramento", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03474497" }, { "nct_id": "NCT01784640", "title": "Pemetrexed Disodium and Hsp90 Inhibitor AUY922 in Treating Patients With Previously Treated Stage IV Non-Small Cell Lung Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Recurrent Non-small Cell Lung Cancer", "Squamous Cell Lung Cancer", "Stage IV Non-small Cell Lung Cancer" ], "interventions": [ { "name": "Hsp90 inhibitor AUY922", "type": "DRUG" }, { "name": "pemetrexed disodium", "type": "DRUG" }, { "name": "pharmacological study", "type": "OTHER" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Jonsson Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 13, "start_date": "2014-01-31", "completion_date": "2018-10-11", "has_results": false, "last_update_posted_date": "2020-09-03", "last_synced_at": "2026-07-24T16:54:10.981Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01784640" }, { "nct_id": "NCT03793179", "title": "Testing the Timing of Pembrolizumab Alone or With Chemotherapy as First Line Treatment and Maintenance in Non-small Cell Lung Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Lung Non-Squamous Non-Small Cell Carcinoma", "Stage IIIB Lung Cancer AJCC v8", "Stage IIIC Lung Cancer AJCC v8", "Stage IV Lung Cancer AJCC v8" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Pemetrexed", "type": "DRUG" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE", "DRUG", "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 600, "start_date": "2019-04-05", "completion_date": "2027-09-30", "has_results": false, "last_update_posted_date": "2026-07-02", "last_synced_at": "2026-07-24T16:54:10.981Z", "location_count": 1082, "location_summary": "Mobile, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 695 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" } ], "official_url": "https://clinicaltrials.gov/study/NCT03793179" }, { "nct_id": "NCT00526890", "title": "Carboplatin, Paclitaxel, Selenomethionine, and Radiation Therapy in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lung Cancer" ], "interventions": [ { "name": "selenomethionine", "type": "DIETARY_SUPPLEMENT" }, { "name": "carboplatin", "type": "DRUG" }, { "name": "paclitaxel", "type": "DRUG" }, { "name": "laboratory biomarker analysis", "type": "OTHER" }, { "name": "radiation therapy", "type": "RADIATION" } ], "intervention_types": [ "DIETARY_SUPPLEMENT", "DRUG", "OTHER", "RADIATION" ], "sponsor": "Roswell Park Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 16, "start_date": "2006-10", "completion_date": "2010-09", "has_results": true, "last_update_posted_date": "2017-11-28", "last_synced_at": "2026-07-24T16:54:10.981Z", "location_count": 1, "location_summary": "Buffalo, New York", "locations": [ { "city": "Buffalo", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00526890" }, { "nct_id": "NCT04424641", "title": "A Study on the Safety of GEN1044 (DuoBody®-CD3x5T4) in Patients With Malignant Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Locally Advanced or Metastatic Solid Tumor(s)", "Prostate Cancer", "Esophageal Cancer", "Triple Negative Breast Cancer (TNBC)", "Squamous Cell Carcinoma of Head and Neck (SCCHN)", "Non-small Cell Lung Cancer (NSCLC)", "Bladder Cancer", "Uterine Cancer" ], "interventions": [ { "name": "GEN1044 is an immunoglobulin G1 (IgG1) bispecific antibody targeting CD3 and 5T4.", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Genmab", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 48, "start_date": "2020-07-15", "completion_date": "2021-10-29", "has_results": true, "last_update_posted_date": "2023-07-25", "last_synced_at": "2026-07-24T16:54:10.981Z", "location_count": 2, "location_summary": "Nashville, Tennessee • Houston, Texas", "locations": [ { "city": "Nashville", "state": "Tennessee" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04424641" }, { "nct_id": "NCT01366131", "title": "Study Evaluating the Safety and Efficacy of MEGF0444A in Combination With Carboplatin, Paclitaxel and Bevacizumab in Patients With Advanced or Recurrent Non-Squamous Non-Small Cell Lung Cancer Who Have Not Received Prior Chemotherapy for Advanced Disease (NILE)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Non-Squamous Non-Small Cell Lung Cancer" ], "interventions": [ { "name": "MEGF0444A", "type": "DRUG" }, { "name": "bevacizumab", "type": "DRUG" }, { "name": "carboplatin", "type": "DRUG" }, { "name": "paclitaxel", "type": "DRUG" }, { "name": "placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Genentech, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 104, "start_date": "2011-06", "completion_date": null, "has_results": false, "last_update_posted_date": "2016-11-02", "last_synced_at": "2026-07-24T16:54:10.981Z", "location_count": 20, "location_summary": "Birmingham, Alabama • Hot Springs, Arkansas • Santa Monica, California + 17 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Hot Springs", "state": "Arkansas" }, { "city": "Santa Monica", "state": "California" }, { "city": "Orlando", "state": "Florida" }, { "city": "Port Saint Lucie", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01366131" }, { "nct_id": "NCT04510129", "title": "A Multicenter Cancer Biospecimen Collection Study", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Cancer of Head and Neck", "Lung Cancer, Nonsmall Cell", "Small-cell Lung Cancer", "Urothelial Carcinoma", "Gastroesophageal Junction Adenocarcinoma", "Cervical Cancer", "Esophageal Squamous Cell Carcinoma", "Triple Negative Breast Cancer", "Hepatocellular Carcinoma", "Renal Cell Carcinoma", "Colorectal Cancer" ], "interventions": [ { "name": "OncoPrism™ assay", "type": "DIAGNOSTIC_TEST" } ], "intervention_types": [ "DIAGNOSTIC_TEST" ], "sponsor": "Cofactor Genomics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1650, "start_date": "2020-02-05", "completion_date": "2027-02", "has_results": false, "last_update_posted_date": "2025-03-12", "last_synced_at": "2026-07-24T16:54:10.981Z", "location_count": 1, "location_summary": "San Francisco, California", "locations": [ { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04510129" }, { "nct_id": "NCT01999673", "title": "Phase 3 Study of Bavituximab Plus Docetaxel Versus Docetaxel Alone in Patients With Late-stage Non-squamous Non-small-cell Lung Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Non-Small-Cell Lung Cancer Stage IIIB", "Non-Small-Cell Lung Cancer Stage IV", "Non-Small-Cell Lung Cancer Metastatic", "Carcinoma, Non-Small-Cell Lung", "Non-Small Cell Lung Cancer", "Non-Small-Cell Lung Carcinoma", "Nonsmall Cell Lung Cancer" ], "interventions": [ { "name": "bavituximab", "type": "BIOLOGICAL" }, { "name": "Docetaxel", "type": "DRUG" }, { "name": "Placebo (for bavituximab)", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "OTHER" ], "sponsor": "Peregrine Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 582, "start_date": "2013-12", "completion_date": "2017-03", "has_results": false, "last_update_posted_date": "2017-04-21", "last_synced_at": "2026-07-24T16:54:10.981Z", "location_count": 39, "location_summary": "Huntsville, Alabama • Chandler, Arizona • Glendale, Arizona + 34 more", "locations": [ { "city": "Huntsville", "state": "Alabama" }, { "city": "Chandler", "state": "Arizona" }, { "city": "Glendale", "state": "Arizona" }, { "city": "Greenbrae", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01999673" } ] }